Back to today’s briefing

Story perspectives

FDA Grants RMAT Designation for Promising Bladder Cancer Therapy

6/27/2025

43 8

Summary

enGene's Cancer Breakthrough

The FDA has awarded enGene's detalimogene voraplasmid the RMAT designation, paving the way for a groundbreaking treatment for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. With a remarkable 71% complete response rate from the phase 1/2 LEGEND trial, this therapy offers hope to patients facing dwindling options in the U.S.

Summary

Sarepta's Gene Therapy Investigation

The FDA is probing two tragic deaths associated with Sarepta Therapeutics' gene therapy, Elevidys, designed for Duchenne muscular dystrophy. Both patients, who were unable to walk, succumbed to acute liver failure. In response, Sarepta has halted shipments for nonambulatory patients and is ramping up safety protocols, emphasizing their commitment to patient well-being.

1 of 2

enGene's Cancer Breakthrough

The FDA has awarded enGene's detalimogene voraplasmid the RMAT designation, paving the way for a groundbreaking treatment for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. With a remarkable 71% complete response rate from the phase 1/2 LEGEND trial, this therapy offers hope to patients facing dwindling options in the U.S.

1 / 2